As it concerns the role displayed by AT1R blockers in the context of breast cancer, it should be noticed that both candesartan and losartan inhibit the AngII-induced expression of VEGF-A, whose expression, along with that of AT1R, was found to correlate with an increase of the microvascular density in breast cancer patients [171]. Here, VEGFA is linked to breast cancer.